ReviewHeart failure reviews2015
Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Review in Heart failure reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.Drug safety · 2018Pooled it
- Cardiomegaly of Unknown Origin: Why Morphology Still Matters in the Genetic Era - A Case of Cardiac Fabry Disease.Medeniyet medical journal · 2026Article
- Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy.International journal of molecular sciences · 2026Article
- Triglyceride-glucose index and systemic immune-inflammation index are associated with left ventricular hypertrophy in type 2 diabetes mellitus patients.BMC endocrine disorders · 2026Article
- Cardiac manifestations of Fabry disease.NPJ cardiovascular health · 2025Review
- Cardiotoxicity Associated with Venlafaxine-Defining Features in a Series of Five Cases and a Call for Proactive Monitoring.Journal of clinical medicine · 2025Article
- Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study.ESC heart failure · 2024Article
- Clinical Applications of Cardiac Magnetic Resonance Parametric Mapping.Diagnostics (Basel, Switzerland) · 2024Review
- Anderson-Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement.Diagnostics (Basel, Switzerland) · 2024Review
- Right Ventricular Myocardial Involvement in Anderson-Fabry Disease at Diagnosis: Evaluation with Three-Dimensional Strain Imaging.Life (Basel, Switzerland) · 2023Article
- Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis).The international journal of cardiovascular imaging · 2023Observational
- Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies.Frontiers in cardiovascular medicine · 2023Review
- Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Article
- The Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2021Article
- Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.Journal of clinical medicine · 2021Review
- Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification.Current cardiology reports · 2021Review
- Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry Disease: Clinical Significance of Discrepant Findings.Radiology. Cardiothoracic imaging · 2020Article
- Cardiomyopathy associated with the Ala143Thr variant of theHeart (British Cardiac Society) · 2020Article
- An Atypical Cardiac Manifestation of Fabry Disease from a Novel Pathological Variant on the GLA Gene.Cureus · 2020Article
- Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy.Frontiers in cardiovascular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme α-galactosidase A (α-Gal A). Anderson-Fabry cardiomyopathy is characterized by structural, valvular, vascular and conduction abnormalities, and is now the most common cause of mortality in patients with AFD. Large-scale metabolic and genetic screening studies have revealed AFD to be prevalent in populations of diverse ethnic origins, and the variant form of AFD represents an unrecognized health burden. Anderson-Fabry disease is an X-linked disorder, and genetic testing is critical for the diagnosis of AFD in women. Echocardiography with strain imaging and cardiac magnetic resonance imaging using late enhancement and T1 mapping are important imaging tools. The current therapy for AFD is enzyme replacement therapy (ERT), which can reverse or prevent AFD progression, while gene therapy and the use of molecular chaperones represent promising novel therapies for AFD. Anderson-Fabry cardiomyopathy is an important and potentially reversible cause of heart failure that involves LVH, increased susceptibility to arrhythmias and valvular regurgitation. Genetic testing and cardiac MRI are important diagnostic tools, and AFD cardiomyopathy is treatable if ERT is introduced early.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.